展会预告 | 亨迪药业邀您相聚CPHI Milan 2026

2026年10月6日-8日，CPHI Milan 2026（世界制药原料展览会）将在Fiera Milano（意大利米兰国际展览中心）盛大举办。湖北亨迪药业股份有限公司将携核心原料药、制剂产品及CDMO服务亮相本次展会，与全球医药同仁共话产业趋势，共拓国际医药合作新空间。

CPHI Milan是全球制药原料行业规模最大、影响力最深远的年度旗舰盛会之一，本次展会以“塑造制药未来”为主题，全新增设了AI与技术、冷链与物流、污染控制等前沿专题展区。据统计，预计将汇聚62000余名参会者、2900余家参展企业及250余位专家学者，涵盖170多个国家和地区，覆盖原料药、制剂、制药机械、包装、生物制药及合同服务等全产业链环节。

CPHI Milan是链接全球制药供应链的核心枢纽，亨迪药业期待借此平台与全球伙伴深入交流，共探行业新趋势，洽谈合作新机遇，欢迎全球医药同仁、合作伙伴及行业专家莅临3J87展位参观指导！

From October 6 to 8, 2026, CPHI Milan 2026, one of the world’s leading pharmaceutical industry exhibitions, will be held at Fiera Milano, Italy.

Hubei Biocause Heilen Pharmaceutical Co., Ltd. will participate in the exhibition, showcasing its portfolio of active pharmaceutical ingredients (APIs), finished dosage forms, and CDMO services. At the event, Biocause Pharma looks forward to engaging with pharmaceutical professionals and industry partners from around the world, sharing insights into emerging industry trends and exploring new opportunities for international collaboration.

As one of the most influential annual events in the global pharmaceutical industry, CPHI Milan brings together key players across the pharmaceutical supply chain. Under the theme “Shaping the Future of Pharma,” the 2026 edition will feature a range of new and emerging areas, including AI & Technology, Cold Chain & Logistics, and Contamination Control. The exhibition is expected to attract more than 62,000 attendees, 2,900 exhibitors, and 250 industry experts and academics from over 170 countries and regions, covering the full pharmaceutical value chain, from APIs and finished formulations to pharmaceutical machinery, packaging, biopharmaceuticals, and contract services.

As a key platform connecting pharmaceutical companies and suppliers across the global value chain, CPHI Milan provides valuable opportunities for industry professionals to exchange ideas, build partnerships, and explore new business opportunities. Biocause Pharma warmly welcomes pharmaceutical professionals, business partners, and industry experts from around the world to visit Booth 3J87.

We look forward to meeting you at CPHI Milan 2026!

图文编辑丨叶梓璇

文字审核丨刘耘

责任编辑丨杨立文

湖北亨迪药业股份有限公司成立于1995年，2021年12月在深圳交易所创业板上市（股票代码:301211），现有员工1000多人，主要从事医药原料药和制剂产品的研发、生产和销售以及CDMO业务。注册地和生产基地位于湖北荆门，研发和销售中心位于武汉。亨迪药业是国家知识产权优势企业、中国医药CDMO企业20强、湖北省博士后医药创新实践基地、湖北省高新技术企业、湖北省专精特新小巨人企业，拥有解热镇痛药物湖北省工程研究中心、湖北省企业技术中心和湖北省抗肿瘤药物企校联合创新中心等三个省级技术平台，目前有90多个医药原料药和制剂品规，服务客户遍及全世界90多个国家和地区，拥有多个符合GMP标准的生产车间和多个CDMO车间。荆门和武汉两个基地共十三次通过欧美官方检查认证，是国内同时通过欧美GMP认证检查的为数不多企业之一。亨迪药业始终坚持“管理规范化、市场国际化、运营精益化、药剂一体化”的发展战略，秉持“科学企业 健康人生”的经营理念，不断提升质量管理水平和技术水平，正朝实现国际有影响力的百年制药企业的目标努力奋斗。